β-微管蛋白Ⅲ,Bcl-2在非小细胞肺癌中的表达及临床意义  

Expression of β-tubulin III and Bcl-2 and the clinical significance in non-small cell lung cancer

作　　者：龚健[1] 刘志良[1] 哈敏文[2] 

机构地区：[1]辽宁医学院附属第一医院胸外科,锦州121001 [2]辽宁医学院附属第一医院肿瘤科,锦州121001

出　　处：《中国新药杂志》2009年第9期815-818,826,共5页Chinese Journal of New Drugs

摘　　要：目的:探讨β-微管蛋白Ⅲ(β-tubulinⅢ),Bcl-2在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法:采用免疫组化SP法检测两种耐药因子在61例NSCLC中的表达。结果:β-tubulinⅢ,Bcl-2在NSCLC组织中表达阳性率分别为73.8%,52.5%,β-tubulinⅢ,Bcl-2在NSCLC阳性表达率大于正常肺组织(P<0.05);β-tubulinⅢ表达阳性率在中-低分化期大于高分化期(P<0.05),Bcl-2表达阳性率在高分化期大于中-低分化期(P<0.05);β-tubulinⅢ阳性表达率晚期大于早期(P<0.05),Bcl-2表达阳性率早期大于晚期(P<0.05);β-tubulinⅢ,Bcl-2在NSCLC中的表达有相关性(P<0.05)。在30例接受紫杉类为基础的化疗的NSCLC中,化疗有效率在β-tubulinⅢ,Bcl-2低表达组和β-tubulinⅢ,Bcl-2高表达组分别为77.8%,61.1%和19.1%,16.7%(即分别为4.1倍和3.7倍),差别有统计学意义(P<0.05)。结论:β-tubulinⅢ,Bcl-2高表达,提示对紫杉类药物耐药;β-tubulinⅢ,Bcl-2是NSCLC的预后因素且其表达与预后相关,可能成为新型的临床预后指标。联合检测非小细胞肺癌组织中耐药因子的表达有益于化疗方案的选择、化疗疗效及预后的判断。Objective： To investigate the expression of β-tubulin and Bcl-2 and their clinical significance in non-small cell lung cancer （NSCLC）. Methods： Expression of β-tubulin Ⅲ and Bel-2 in NSCLC tissues of 61 patients was detected by immunohistoehemieal method. Results： The positive rates of β-tubulin Ⅲ and Bcl- 2 in NSCLC were 73.8% and 52.5%. The positive rates of β-tubulin Ⅲ and Bcl-2 were higher in NSCLC than in normal lung tissues （P 〈 0.05）. The positive rate of β-tubulin Ⅲ in NSCLC with moderate to low differentiation was higher than in that with high differentiation （P 〈 0.05）. The positive rate of Bcl-2 in NSCLC with high differentiation was higher than in that with moderate to low differentiation （ P 〈 0.05 ）. The positive rates of β-tubulin Ⅲ in late stage was higher than those in early stage （P 〈 0.05）. The positive rates of Bel-2 in early stage was higher than those in late stage （P 〈 0.05 ）. The expression of β-tubulin Ⅲ closely related to that of Bel-2 in NSCLC （P 〈 0.05）. A total of 30 NSCLC patients were treated with chemotherapy regiment containing Taxane. The response rates in low-expression/over-expression of β-tubulin Ill and Bcl-2 were 77.8 %/19.1% and 61.1%/16.7 % （4.1 and 3.7 times, P 〈 0.05 ）. Conclusion ： High level of β-tubulin Ⅲ and Bel-2 expression shows a resistance to taxane ; the expressions of β-tubulin Ⅲ and Bcl-2 correlate with prognosis in NSCLC, whieh may become a new indicator of prognosis. Their deteetion is helpful to the choiee of the drug of chemotherapy and prediction of prognosis.

关 键 词：非小细胞肺癌 β-tubulinⅢ BCL-2 紫衫醇 耐药 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]